Jack Anders - May 3, 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Chief Financial Officer
Signature
/s/ Jack Anders
Stock symbol
RVMD
Transactions as of
May 3, 2024
Transactions value $
-$373,460
Form type
4
Date filed
5/3/2024, 07:36 PM
Previous filing
Mar 20, 2024
Next filing
Jun 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $26.8 K +10 K +9.81% $2.68 112 K May 3, 2024 Direct F1, F2
transaction RVMD Common Stock Sale -$400 K -10 K -8.93% $40.03 102 K May 3, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -10 K -43.83% $0.00 12.8 K May 3, 2024 Common Stock 10 K $2.68 Direct F1

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023.
F2 Includes 60,250 restricted stock units.
F3 This transaction was executed in multiple trades in prices ranging from $40.00 to $40.13, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.